A Tony Coles Parkin­son's biotech, Yu­man­i­ty, con­tin­ues its back­slide as lead pro­gram earns a par­tial hold

A Tony Coles biotech look­ing to de­vel­op new drugs for Parkin­son’s dis­ease and oth­er neu­ro­log­i­cal con­di­tions ran in­to trou­ble Wednes­day as the FDA slapped its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER